PLANADIX LIQUIZ
NADPHARMADIC PRODUCTION
Identification
- Active ingredient (INN)
- PARACETAMOL
- Internal code
- 03 B 126
- Country of Origin
- Algeria
- Pharmaceutical form
- Oral Suspension (Single-dose Stick)
- Prescription List
- OTC
- Packaging
- B/12
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
Symptomatic treatment of mild to moderate pain and/or febrile state, which is reserved for children aged 16-48 kg (approximately 4-15 years).
Mechanism of Action
Pharmacotherapeutic group: other analgesics and antipyretic analides, code: ATC: N02BE01.
N: Central nervous system.
Mechanism of action
Paracetamol has a central and peripheral mechanism of action.
Adverse Effects
Immune system disorders.
- Rare: hypersensitivity reactions to anaphylactic shock type, and oedema of Quincke.
Their occurrence requires the definitive cessation of this medicine and related medicines Skin and tissue disorders under skin.
- Rare: erythema, urticaria, skin rash have been reported.
Their occurrence requires the definitive cessation of this medicine and related medicines Very rare cases of serious skin adverse reactions have been reported.
- Not known: fixed pigmented erythema.
Blood and lymphatic disorders
Very unusual: thrombocytopenia, leukopenia and neutropenia.
- Not known: agranulocytosis, hemolytic anaemia in patients with glucose deficiency ‐ 6 ‐ phosphate ‐ dehydrogenase.
Hepatobiliary disorders.
- Not known: increased transaminases, cytolytic liver disease, acute hepatitis, massive hepatitis in particular when used in a risk situation.
Undetermined adverse events: a suspected drug with a suspected drug or a suspected drug with a drug known as a drug called a drug called a drug called a drug called a drug called a drug called a drug called a drug.